Opis działalności
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.
Zarząd & Rada nadzorcza
| CEO |
| Christopher A. Viehbacher |
| Zarząd |
| Michael McDonnell, Dr. Ginger Gregory, Rachid Izzar, Susan H. Alexander, Nicole Murphy, Priya Singhal |
| Rada nadzorcza |
| Caroline Dorsa, Eric K. Rowinsky, Jesus B. Mantas, Maria C. Freire, Stephen A. Sherwin, William A. Hawkins, Susan Langer, Christopher A. Viehbacher |
Dane firmy
| Nazwa: |
Biogen Inc. |
| Adres: |
225 Binney Street,Cambridge, Massachusetts 02142, USA |
| Telefon: |
+1 781-464-2000 |
| Fax: |
+1-617-679-2617 |
| E-mail: |
-
|
| Internet: |
www.biogen.com |
| Przemysł: |
Biotechnologia |
| Sektor: |
Biotechnologia |
| Podsektor: |
Biotechnologia |
| Koniec roku finansowego: |
31.12 |
| Free float: |
72,20% |
| Data IPO: |
- |
Relacje inwestorskie
| Nazwa: |
Karen Jewell |
| Telefon: |
781-464-2442 |
| Fax: |
- |
| E-mail: |
IR@biogenidec.com
|
